The estimated Net Worth of Martyn D Greenacre is at least $396 Tausend dollars as of 23 January 2019. Mr. Greenacre owns over 18,500 units of Curis Inc stock worth over $133,054 and over the last 21 years he sold CRIS stock worth over $19,425. In addition, he makes $243,361 as Independent Chairman of the Board at Curis Inc.
Sign up
Mr. Greenacre CRIS stock SEC Form 4 insiders trading
Martyn has made over 6 trades of the Curis Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 18,500 units of CRIS stock worth $19,425 on 23 January 2019.
The largest trade he's ever made was exercising 80,000 units of Curis Inc stock on 28 March 2012 worth over $117,600. On average, Martyn trades about 7,950 units every 83 days since 2003. As of 23 January 2019 he still owns at least 26,089 units of Curis Inc stock.
You can see the complete history of Mr. Greenacre stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Martyn Greenacre biography
Martyn D. Greenacre serves as Independent Chairman of the Board of the Company. He currently serves as Independent Director of the Company. He has served on board since February 2000 and was a director of Creative BioMolecules, Inc., a predecessor life science company, from June 1993 to July 2000. Mr. Greenacre has served as Chairman of Life Mist L.L.C., a privately-held company in the field of fire suppression, since September 2001. From June 1997 to June 2001, Mr. Greenacre was Chief Executive Officer of Delsys Pharmaceutical Corporation, a drug formulation company. From 1993 to 1997, Mr. Greenacre was President and Chief Executive Officer of Zynaxis, Inc., a biopharmaceutical company. Prior to Zynaxis, Inc., Mr. Greenacre served in various senior management positions at SmithKline Beecham, a pharmaceuticals company, from 1973 through 1992. Mr. Greenacre also serves as a director of Neostem, Inc., and Formula Pharmaceuticals. Previously, Mr. Greenacre served as a director of Acusphere, Inc., Cephalon, Inc. and Orchestra Therapeutics, Inc., and as a director and Chairman of BMP Sunstone Corporation. Mr. Greenacre received an M.B.A. from Harvard Business School and a B.A. from Harvard College.
What is the salary of Martyn Greenacre?
As the Independent Chairman of the Board of Curis Inc, the total compensation of Martyn Greenacre at Curis Inc is $243,361. There are 6 executives at Curis Inc getting paid more, with James Dentzer having the highest compensation of $1,557,770.
How old is Martyn Greenacre?
Martyn Greenacre is 78, he's been the Independent Chairman of the Board of Curis Inc since 2017. There are no older and 10 younger executives at Curis Inc.
What's Martyn Greenacre's mailing address?
Martyn's mailing address filed with the SEC is 128 SPRING STREET, BUILDING C - SUITE 500, LEXINGTON, MA, 02421.
Insiders trading at Curis Inc
Over the last 24 years, insiders at Curis Inc have traded over $10,321,234 worth of Curis Inc stock and bought 10,678,594 units worth $25,596,192 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Discovery Technologies Ltd ... und James R Mcnab. On average, Curis Inc executives and independent directors trade stock every 62 days with the average trade being worth of $811,553. The most recent stock trade was executed by James E Dentzer on 27 January 2022, trading 5,500 units of CRIS stock currently worth $17,160.
What does Curis Inc do?
curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis’s pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl
What does Curis Inc's logo look like?
Complete history of Mr. Greenacre stock trades at Curis Inc
Curis Inc executives and stock owners
Curis Inc executives and other stock owners filed with the SEC include:
-
James Dentzer,
President, Chief Executive Officer, Director -
James E. Dentzer,
Pres, CEO & Director -
Robert Martell,
Head - Research and Development -
William Steinkrauss,
Chief Financial Officer -
Dr. Robert E. Martell,
Head of R&D -
William E. Steinkrauss,
Chief Financial Officer -
Martyn Greenacre,
Independent Chairman of the Board -
Kenneth Kaitin,
Independent Director -
Marc Rubin,
Independent Director -
Lori Kunkel,
Independent Director -
Elif McDonald,
VP of Investor Relations & Corp. Communications -
Dr. Reinhard Wilhelm von Roemeling,
Sr. VP of Clinical Devel. -
Mark W. Noel,
VP of Technology Management & Intellectual Property -
John Hohneker,
Director -
James R Mcnab,
Director -
David Tuck,
Chief Medical Officer -
Ali Ph.D. Fattaey,
President & COO -
Kenneth Pienta,
Director -
Discovery Technologies Ltd ...,
-
Douglas Melton,
Director -
Lee L Rubin,
Senior Vice President,Research -
Mary Elizabeth Potthoff,
Vice President,General Counsel -
Mani Mohindru,
Sr. VP, Corp. Strategy & IR -
Christopher U Missling,
Sr. Vice President, Finance -
Ruth B Kunath,
Director -
Jaye Viner,
Chief Medical Officer -
Michael Gray,
Chief Financial Officer -
James R Tobin,
Director -
Mark Noel,
Vice President, Tech. Manage. -
Maurizio Voi,
Chief Medical Officer -
Joseph Md Phd Davie,
Director -
Susan B Bayh,
Director -
Changgeng Qian,
VP, Research & Preclinical Dev -
Capital Management, Llcra C...,
-
Partners L P/Ilbiotechnolog...,
-
Stephen Carter,
Director -
Mitchell Keegan,
Vice-President -
Joseph M Davie,
Director -
Daniel R Passeri,
President and CEO -
Anne Elizabeth Borgman,
Director -
Diantha Duvall,
CFO -
Jonathan B. Zung,
CDO